FDA
-
-
-
-
-
-
-
Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG
-
-
-
-
-
-
-
Harmony Biosciences phase 3 trial for Fragile X syndrome fails primary endpoint
-
-
-
-
-
-
-
Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Harmony Biosciences Holdings Inc. (HRMY)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)
-
-
-
-
-
-
-
Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
-
-
-
-
-
-
-
Harmony Biosciences (HRMY) Receives U.S. Food And Drug Administration Approval For Wakix In Pediatric Patients With Narcolepsy
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

